Skip to content

SULFAMETHOXAZOLE AND TRIMETHOPRIM

DRUG15 trials

Sponsors

Debiopharm International S.A., Uppsala Universitet, Rigshospitalet, Miltenyi Biomedicine GmbH, Centre Hospitalier Regional Universitaire De Tours

Conditions

Benign Prostate HyperplasiaCatheter related bloodstream infections due to Staphylococcus aureusGlioblastomaGram-negative bacteraemiaKidney Transplant recipientsPatients with hip or knee infectionsPatients with relapsing-remitting multiple sclerosis with less than 10 years disease duration.Periprosthetic hip joint infection Periprosthetic knee joint infection

Phase 1

Phase 2

Phase 3

Phase 4

Early shift to oral antibiotic treatment of pyogenic vertebral osteomyelitis – a open label non-inferiority randomized nationwide study.
RecruitingCTIS2023-507617-96-01
RigshospitaletPyogenic vertebral osteomyelitis
Start: 2024-02-14Target: 530Updated: 2025-01-08
SHORTCUT - Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients, a multicenter randomized non-inferiority trial
RecruitingCTIS2024-513328-40-00
Assistance Publique Hopitaux De Paris, Assistance Publique Hopitaux De ParisKidney Transplant recipients, Pyelonephritis
Start: 2024-03-25Target: 470Updated: 2024-06-19
Evaluation of the clinical implementation of biofilm susceptibility to antibiotics using Minimum Biofilm Eradication Concentration (MBEC) in addition to Minimum Inhibitory Concentration (MIC) to guide the treatment of periprosthetic joint infections; a prospective randomized clinical trial
Not yet recruitingCTIS2024-518350-17-00
Vaestra GoetalandsregionenPeriprosthetic hip joint infection Periprosthetic knee joint infection
Target: 64Updated: 2024-10-23
Early oral step-down antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial)
RecruitingCTIS2024-517308-13-00
Tan Tock Seng Hospital Pte. Ltd.Gram-negative bacteraemia
Start: 2025-12-10Target: 160Updated: 2025-11-10
The DALBA-study Introduction of the antibiotic dalbavancin in orthopaedic surgery – an evaluation of: • Health economic costs • Patient-reported outcomes on quality of life • Local bone and soft tissue concentrations • Effect on the gut microbiome A randomised controlled study of dalbavancin versus standard antibiotic treatment of Gram-positive periprosthetic joint infections.
RecruitingCTIS2025-522088-13-00
Region MidtjyllandPeriprosthetic joint infection
Start: 2025-12-12Target: 50Updated: 2025-12-05
TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial
Not yet recruitingCTIS2025-520940-14-00
Assistance Publique Hopitaux De ParisPyogenic liver abscess
Target: 456Updated: 2025-10-06
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
Not yet recruitingCTIS2024-516232-10-00
Centre Hospitalier Universitaire De NimesSerious infections in critically ill patients treated with antibiotics
Target: 200Updated: 2025-10-17

Related Papers